BioSpace News Archive

Apnimed today announced the dosing of the first patient in the Phase 2b MARIPOSA study of AD109, the company’s lead investigational oral medication for the treatment of OSA.

Ampio Pharmaceuticals today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed with cancer.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial.

Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer test that includes both cell-based and cell-free analysis from a single blood draw.

INVO Bioscience, Inc., a medical device company focused on commercializing the world’s only in vivo culture system, INVOcell®, announced the Company has entered into an expanded agreement with Ovoclinic, a group of clinics specialized in assisted reproductive treatments with four locations across Spain and collaborating centers around Europe, to accelerate adoption of INVOcell within their markets.

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.

Viome Life Sciences (VLS) announces the publication of a clinical study performed with leading researchers and clinicians for early detection of life-threatening cancer or its precursors, and the launch of its Grants Program to encourage collaborative research.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update on the Company’s first product candidate, the IL-6 test for sepsis triage.

Legend Biotech Corporation announced that it has priced an underwritten public offering of 7,500,000 American depositary shares, each representing two ordinary shares, at a public offering price of $40.00 per ADS, for total gross proceeds of approximately $300.0 million.